Authors: Ruth E. Cooper, Emma Williams, Seth Seegobin, Charlotte Tye, Jonna Kuntsi, Philip Asherson European Neuropsychopharmacology, August 2017
— Adults with ADHD describe self-medicating with cannabis, with some reporting a preference for cannabis over ADHD medications. A small number of psychiatrists in the US prescribe cannabis medication for ADHD, despite there being no evidence from randomised controlled studies…
Authors: Ciara A. Torres, Carl L. Hart American Journal of Obstetrics and Gynecology, August 2017
— To the Editors: We read with interest the article by Chasnoff, 1 which concluded that physicians should be educated about the negative effects of marijuana use during pregnancy and should discourage its use by pregnant women and women considering becoming pregnant. In our view…
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Sarah Russohttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngSarah Russo2017-08-01 07:45:102020-03-23 07:39:29Marijuana and pregnancy: objective education is good, but biased education is not.
Authors: Jessica Freundt-Revilla, Kristel Kegler, Wolfgang Baumgärtner, Andrea Tipold PLoS One, 10 July 2017
— The endocannabinoid system is a regulatory pathway consisting of two main types of cannabinoid receptors (CB1 and CB2) and their endogenous ligands, the endocannabinoids. The CB1 receptor is highly expressed in the central and peripheral nervous systems (PNS) in mammalians and…
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Sarah Russohttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngSarah Russo2017-07-10 10:34:152019-07-29 17:59:03Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system.
Authors: Kerstin Iffland, Franjo Grotenhermen Cannabis and Cannabinoid Research, 1 June 2017
— Introduction: This literature survey aims to extend the comprehensive survey performed by Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with o…
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Sarah Russohttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngSarah Russo2017-06-01 19:41:122019-06-17 07:01:46An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.
Authors: Susan A. Stoner Alcohol & Drug Abuse Institute, University of Washington, June 2017
— THC and CBD appear to have antidepressant-like effects in animal models at certain doses but not others. Marijuana has been associated with diminished motivation, but a distinct “cannabis amotivational syndrome” has yet to be substantiated. Studies looking at whether marijuana…
Authors: Andras Bilkei-Gorzo, Onder Albayram, Astrid Draffehn, Kerstin Michel, Anastasia Piyanova, Hannah Oppenheimer, Mona Dvir-Ginzberg, Ildiko Rácz, Thomas Ulas, Sophie Imbeault, Itai Bab, Joachim L Schultze, Andreas Zimmer Nature Medicine, 8 May 2017
— The balance between detrimental, pro-aging, often stochastic processes and counteracting homeostatic mechanisms largely determines the progression of aging. There is substantial evidence suggesting that the endocannabinoid system (ECS) is part of the latter system because it m…
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Sarah Russohttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngSarah Russo2017-05-08 17:22:262020-03-20 03:47:38A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice
A roundtable discussion featuring Society of Cannabis Clinician’s members Dr. Bonni Goldstein, Dr. Dustin Sulak, and Dr. Jeffrey Hergenrather on the applications of cannabis in pediatric care. They share case studies on treating kids and adolescents in their clinical practice with autism, epilepsy, and other conditions.
Authors: Brooke K. O’Connell, David Gloss, Orrin Devinsky Epilepsy & Behavior, May 2017
— Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been used to treat epilepsy for millennia, but only in the last few years have we begun to collect data from adequ…
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Sarah Russohttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngSarah Russo2017-05-01 15:53:162020-03-23 07:30:13Cannabinoids in treatment-resistant epilepsy: A review.
Authors: Assaf Shelef, Yoram Barak, Uri Berger, Diana Paleacu, Shelly Tadger, Igor Plopsky, Yehuda Baruch Expert Opinion on Pharmacotherapy, April 2017
— Neuropsychiatric symptoms (NPS) in Alzheimer’s disease (AD) are associated with significant negative outcomes for patients and their caregivers. Agitation, one of the most distressing NPS, lacks safe and effective long term interventions. Nonpharmacological interventions are s…
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Sarah Russohttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngSarah Russo2017-04-01 17:07:172020-03-20 03:49:41An update on the advancements in the treatment of agitation in Alzheimer’s disease
Authors: Georgia Watt, Tim Karl Frontiers in Pharmacology, 3 February 2017
— Alzheimer’s disease (AD) is a debilitating neurodegenerative disease that is affecting an increasing number of people. It is characterized by the accumulation of amyloid-β and tau hyperphosphorylation as well as neuroinflammation and oxidative stress. Current AD treatments do…
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Sarah Russohttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngSarah Russo2017-02-03 16:56:412020-03-20 03:50:00In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer’s Disease
Authors: Mario Stampanoni Bassi, Andrea Sancesario, Roberta Morace, Diego Centonze, Ennio Iezzi Cannabis and Cannabinoid Research, February 2017
— The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably compl…
Authors: Renata Androvicova, Jiri Horacek, Tibor Stark, Filippo Drago, Vincenzo Micale Pharmacological Research, January 2017
— The endocannabinoid system (ECS), which is composed of the cannabinoid receptors types 1 and 2 (CB1 and CB2) for marijuana’s psychoactive ingredient Δ9-tetrahydrocannabinol (Δ9-THC), the endogenous ligands (AEA and 2-AG) and the enzymatic systems involved in their biosynthesis…
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Sarah Russohttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngSarah Russo2017-01-01 14:04:042020-03-19 14:09:54Endocannabinoid system in sexual motivational processes: Is it a novel therapeutic horizon?
Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.
Authors: Ruth E. Cooper, Emma Williams, Seth Seegobin, Charlotte Tye, Jonna Kuntsi, Philip Asherson
European Neuropsychopharmacology, August 2017
—
Adults with ADHD describe self-medicating with cannabis, with some reporting a preference for cannabis over ADHD medications. A small number of psychiatrists in the US prescribe cannabis medication for ADHD, despite there being no evidence from randomised controlled studies…
Marijuana and pregnancy: objective education is good, but biased education is not.
Authors: Ciara A. Torres, Carl L. Hart
American Journal of Obstetrics and Gynecology, August 2017
—
To the Editors: We read with interest the article by Chasnoff, 1 which concluded that physicians should be educated about the negative effects of marijuana use during pregnancy and should discourage its use by pregnant women and women considering becoming pregnant. In our view…
Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system.
Authors: Jessica Freundt-Revilla, Kristel Kegler, Wolfgang Baumgärtner, Andrea Tipold
PLoS One, 10 July 2017
—
The endocannabinoid system is a regulatory pathway consisting of two main types of cannabinoid receptors (CB1 and CB2) and their endogenous ligands, the endocannabinoids. The CB1 receptor is highly expressed in the central and peripheral nervous systems (PNS) in mammalians and…
An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.
Authors: Kerstin Iffland, Franjo Grotenhermen
Cannabis and Cannabinoid Research, 1 June 2017
—
Introduction: This literature survey aims to extend the comprehensive survey performed by Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with o…
Effects of Marijuana on Mental Health: Depression.
Authors: Susan A. Stoner
Alcohol & Drug Abuse Institute, University of Washington, June 2017
—
THC and CBD appear to have antidepressant-like effects in animal models at certain doses but not others. Marijuana has been associated with diminished motivation, but a distinct “cannabis amotivational syndrome” has yet to be substantiated. Studies looking at whether marijuana…
A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice
Authors: Andras Bilkei-Gorzo, Onder Albayram, Astrid Draffehn, Kerstin Michel, Anastasia Piyanova, Hannah Oppenheimer, Mona Dvir-Ginzberg, Ildiko Rácz, Thomas Ulas, Sophie Imbeault, Itai Bab, Joachim L Schultze, Andreas Zimmer
Nature Medicine, 8 May 2017
—
The balance between detrimental, pro-aging, often stochastic processes and counteracting homeostatic mechanisms largely determines the progression of aging. There is substantial evidence suggesting that the endocannabinoid system (ECS) is part of the latter system because it m…
Physician Roundtable – Cannabis in Pediatrics
A roundtable discussion featuring Society of Cannabis Clinician’s members Dr. Bonni Goldstein, Dr. Dustin Sulak, and Dr. Jeffrey Hergenrather on the applications of cannabis in pediatric care. They share case studies on treating kids and adolescents in their clinical practice with autism, epilepsy, and other conditions.
Cannabinoids in treatment-resistant epilepsy: A review.
Authors: Brooke K. O’Connell, David Gloss, Orrin Devinsky
Epilepsy & Behavior, May 2017
—
Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been used to treat epilepsy for millennia, but only in the last few years have we begun to collect data from adequ…
An update on the advancements in the treatment of agitation in Alzheimer’s disease
Authors: Assaf Shelef, Yoram Barak, Uri Berger, Diana Paleacu, Shelly Tadger, Igor Plopsky, Yehuda Baruch
Expert Opinion on Pharmacotherapy, April 2017
—
Neuropsychiatric symptoms (NPS) in Alzheimer’s disease (AD) are associated with significant negative outcomes for patients and their caregivers. Agitation, one of the most distressing NPS, lacks safe and effective long term interventions. Nonpharmacological interventions are s…
In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer’s Disease
Authors: Georgia Watt, Tim Karl
Frontiers in Pharmacology, 3 February 2017
—
Alzheimer’s disease (AD) is a debilitating neurodegenerative disease that is affecting an increasing number of people. It is characterized by the accumulation of amyloid-β and tau hyperphosphorylation as well as neuroinflammation and oxidative stress. Current AD treatments do…
Cannabinoids in Parkinson’s Disease.
Authors: Mario Stampanoni Bassi, Andrea Sancesario, Roberta Morace, Diego Centonze, Ennio Iezzi
Cannabis and Cannabinoid Research, February 2017
—
The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably compl…
Endocannabinoid system in sexual motivational processes: Is it a novel therapeutic horizon?
Authors: Renata Androvicova, Jiri Horacek, Tibor Stark, Filippo Drago, Vincenzo Micale
Pharmacological Research, January 2017
—
The endocannabinoid system (ECS), which is composed of the cannabinoid receptors types 1 and 2 (CB1 and CB2) for marijuana’s psychoactive ingredient Δ9-tetrahydrocannabinol (Δ9-THC), the endogenous ligands (AEA and 2-AG) and the enzymatic systems involved in their biosynthesis…